TECON(SZ:002100)2022-12-05 01:16Group 1: Vaccine Revenue Growth - Vaccine revenue showed stable growth in the first half of the year, with significant profit increase compared to the same period last year. This is attributed to the completion of technical upgrades in the foot-and-mouth disease vaccine production, resolving capacity bottlenecks and creating a new profit growth point [2]. - Continuous improvements in advanced production technology and operational processes have significantly increased product qualification rates and reduced production costs, leading to an increase in gross profit margin [2]. - The company received approval for tax incentives, further enhancing profitability [2]. Group 2: Product Development and Market Expansion - The company is the first in China to produce avian influenza vaccines using suspension technology, with production approval obtained in February 2017, laying a foundation for high growth [2]. - The review and inspection of the pig fever E2 vaccine have been completed, with expectations to obtain production approval by the end of 2017, enriching the company's vaccine product line [2]. - Despite a continuous decline in pig prices, the company's increased output and improved internal management and breeding technology have minimized profit decline in this sector, with plans to accelerate pig farming industry layout in Xinjiang and Henan regions [2].